Athira Pharma
ATHA
Market cap $14.8M

0.3801 USD

+0.0231

6.47%

Updated Jul 31, 11:17 AM EDT

1 day

6.47%

5 days

-16.81%

1 month

25.86%

3 months

34.98%

6 months

-27.64%

Year to date

-30.90%

1 year

-88.08%

5 years

-97.78%

10 years

-97.78%

About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Employees: 26

Healthcare Biotechnology

0

Funds holding %

of 7,324 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

300% more call options, than puts

Call options by funds: $4K | Put options by funds: $1K

1.36% less ownership

Funds ownership: 46.35% [Q4 2024] → 44.99% (-1.36%) [Q1 2025]

4% less funds holding

Funds holding: 56 [Q4 2024] → 54 (-2) [Q1 2025]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

52% less capital invested

Capital invested by funds: $10.5M [Q4 2024] → $5M (-$5.51M) [Q1 2025]

65% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 20

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ATHA.

See Analyst Rankings

Financial journalist opinion

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Seattle-area biotech company Athira Pharma agreed to pay $4.

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association's 35th International Symposium on ALS/MND, taking place Dec. 6-8, 2024, in Montreal, Canada.

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Zacks Investment Research

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

On Wednesday, Athira Pharma, Inc. ATHA stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks

See News Rankings

Charts implemented using Lightweight Charts™